Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 02, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,275,000 ordinary shares of 25 pence each.
- Purchase Price: 1,222.26 pence per share.
- Treasury Holdings: Following the purchase, the company holds 475,339,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.56% of total voting rights.
- Shares in Issue: 5,549,863,601 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 2,275,000 shares on November 02, 2007. Consequently, the total number of shares held in Treasury increased to 475,339,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,549,863,601) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (475,339,158) and its impact on total voting rights (8.56%).
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.